NVO Aug 2024 130.000 put
- Yahoo Finance Video
Weight-loss drugs linked to rare vision loss: Harvard study
Novo Nordisk (NVO) and Eli Lilly (LLY) shares dip in reaction to a Harvard study that found GLP-1 weight-loss drugs Ozempic and Wegovy could be linked to rare cases of vision loss. Yahoo Finance health reporter Anjalee Khemlani explains the study's findings. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Luke Carberry Mogan.
- Bloomberg
Ozempic Linked to Rare Cases of Vision Loss in Harvard Study
(Bloomberg) -- Novo Nordisk A/S’ best-selling diabetes and weight-loss drugs Ozempic and Wegovy appear to be associated with a higher risk of a rare form of vision loss, according to an analysis by doctors at Massachusetts Eye and Ear, a Harvard-affiliated hospital.Most Read from BloombergUS Allies Say China Is Developing Attack Drones for RussiaChina Can End Russia’s War in Ukraine With One Phone Call, Finland SaysZelenskiy Challenges Trump to Reveal Plans for Ending WarDemocrats Weigh Mid-July
- Insider Monkey
Should You Hold Novo Nordisk A/S (NVO) for the Long Term?
Artisan Partners, an investment management company, released its “Artisan Global Equity Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here. The expectation of rate reduction later this year and slowing inflation boosted global markets in Q1. In the first quarter, the fund’s Investor Class ARTHX returned 12.67 %, Advisor […]
